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Aims Atrial fibrillation (AF) is a common arrhythmia associated with an increased stroke risk. The use of multivariable pre-
diction models could result in more efficient primary AF screening by selecting at-risk individuals. We aimed to deter-




We performed a systematic review on multivariable models derived, validated, and/or augmented for AF prediction in
community cohorts using Pubmed, Embase, and CINAHL (Cumulative Index to Nursing and Allied Health Literature)
through 1 August 2019. We performed meta-analysis of model discrimination with the summary C-statistic as the pri-
mary expression of associations using a random effects model. In case of high heterogeneity, we calculated a 95% pre-
diction interval. We used the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction
Modelling Studies) checklist for risk of bias assessment. We included 27 studies with a total of 2 978 659 unique par-
ticipants among 20 cohorts with mean age ranging from 42 to 76 years. We identified 21 risk models used for incident
AF risk in community cohorts. Three models showed significant summary discrimination despite high heterogeneity:
CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology) [summary C-statistic 0.71; 95% confi-
dence interval (95% CI) 0.66–0.76], FHS-AF (Framingham Heart Study risk score for AF) (summary C-statistic 0.70;
95% CI 0.64–0.76), and CHA2DS2-VASc (summary C-statistic 0.69; 95% CI 0.64–0.74). Of these, CHARGE-AF and
FHS-AF had originally been derived for AF incidence prediction. Only CHARGE-AF, which comprises easily obtainable
measurements and medical history elements, showed significant summary discrimination among cohorts that had ap-
plied a uniform (5-year) risk prediction window.
...................................................................................................................................................................................................
Conclusion CHARGE-AF appeared most suitable for primary screening purposes in terms of performance and applicability in
older community cohorts of predominantly European descent.
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Introduction
Atrial fibrillation (AF) is a common cardiac arrhythmia affecting over
33 million people worldwide.1 Its incidence increases with age, with a
lifetime risk of over 30%.2 Due to ageing populations, the number of
AF cases in Europe is expected to double to >17 million by 2060.3
Atrial fibrillation is associated with a five-fold increased risk of ischae-
mic stroke, which can be largely prevented by antithrombotic pro-
phylaxis in at-risk patients.4,5
Screening for AF in the community has been proposed as an ap-
proach to optimize early AF detection and to prevent AF-associated
sequelae.6 Prior research has shown that AF screening is cost-
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effective when selecting patients at older age, with thresholds for
screening eligibility varying from 65 to 75 years.7–9 The screening
regimes in these primary care studies often involved single-point
screening, while multiple-point screening could result in a higher yield
of new AF cases.9,10 Multiple-point or prolonged rhythm monitoring
schemes are, however, likely to be more costly for society and more
burdensome to patients.7–9 Multivariable prediction models for inci-
dent AF could contribute to AF screening by determining a risk cate-
gory for each patient.11 The more intensive regimes could be
assigned to those with highest risk, while those in lower-risk strata
could be assigned to less stringent follow-up, or none at all. It
remains, however, insufficiently clear from consensus documents
whether other parameters beyond age could be used to differentiate
between degrees of AF risk within the community.5,12
We therefore set out to perform a systematic review and meta-
analysis with two aims. First, we wished to provide an overview of AF
risk models that are applicable to and have been validated in commu-
nity cohorts. Such models should consist of variables that can be
quickly assessed and/or are commonly available from patient records
and should not require advanced diagnostic testing. Second, by syn-
thesizing the discriminatory abilities of each included risk model, we
aimed to determine which of these may be best suitable for increas-
ing efficiency of future primary AF screening efforts.
Methods
We reported this systematic review and meta-analysis in accordance
with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines.13
Data searches
We searched Pubmed, Embase, and Cumulative Index to Nursing and
Allied Health Literature (CINAHL) databases from inception through 1
August 2019. We used the keywords ‘AF or atrial flutter (AFl)’ and ‘risk
model’ as well as related terms. We filtered for studies conducted on
humans and written in English. The full search is shown in Supplementary
material online, Table S1. We checked the reference list of included stud-
ies for additional relevant references.
Study selection
To be eligible for inclusion, studies had: (i) to be original studies in adults
(>_18 years of age); (ii) to derive, validate, and/or augment a tool for
predicting risk of incident AF/AFl based on multivariable analysis; (iii) to
include only patients without a diagnosis of AF/AFl at baseline; and (iv) to
incorporate into their risk prediction tool only variables that are applica-
ble and/or commonly available in primary care settings. We included
studies with AFl as co-outcome, since AF and AFl have similar clinical rel-
evance.5 In light of inclusion criterion iv, we included only studies that
used medical history, physical examination, simple laboratory findings, or
electrocardiogram (ECG) parameters as variables in the prediction
model. We excluded studies that required advanced diagnostic testing
[e.g. echocardiography, genetic markers, or specialized (laboratory) tests]
for their simple (non-augmented) model. We only included studies writ-
ten in English. We included studies that diagnosed AF/AFl through medi-
cal records, hospitalizations, death certificates, and/or ECG during
follow-up examinations. We excluded studies that selected patients for a
common disease or risk factor, as such studies would not be generalizable
to the community. Moreover, we excluded studies with a mean follow-
up duration under 3 months since with shorter follow-up durations there
would be an increasing risk of measuring prevalent AF missed at baseline
recording, rather than actual incident AF. We uploaded references to a
systematic review web application (Covidence, Veritas Health Innovation
Ltd, Melbourne, Australia). Three investigators (J.C.L.H., L.V., and R.E.H.)
assessed studies for eligibility by screening studies on title and abstract,
followed by a full-text screening. Disagreements were resolved by panel
discussion (J.C.L.H., L.V., R.E.H., and W.A.M.L.).
Data extraction and quality assessment
Two investigators (J.C.L.H. and L.V.) extracted data from the included
studies regarding study methods, population characteristics, risk predic-
tion model(s), and model performance. For the latter, we extracted the
C-statistic and corresponding 95% confidence interval (95% CI) for dis-
crimination, and the P-value of a goodness-of-fit test and the ratio of ob-
served and expected AF/AFl cases (O:E ratio) for calibration. When
authors did not report an O:E ratio we derived the O:E ratio by analysing
calibration plots.14 When authors performed augmentation of pre-
existing models by adding variables with an aim to enhance predictive
value of models, we retrieved the net reclassification improvement (NRI)
index of the augmented model compared with the original ‘simple’ model,
as well as the augmented model’s performance in terms of discrimination
and calibration. We included augmentation data only when the augmen-
tation variables were applicable to primary care settings as outlined
previously.
Two investigators (J.C.L.H. and L.V.) used the Critical Appraisal and
Data Extraction for Systematic Reviews of Prediction Modelling Studies
(CHARMS) checklist to assess the risk of bias and the applicability for our
research aims.15 Our interpretation of each CHARMS domain can be
found in the Supplementary material online, Methods. We assessed risk of
bias at the cohort level for each of the included studies. We scored each
domain as either low, unclear, or high risk of bias. We defined overall risk
of bias as: low, when all domains of a cohort within one study were
scored as low risk of bias; unclear, when one or more domains of a co-
hort within one study were scored as unclear risk of bias; and high, when
one or more domains of a cohort within one study were scored as high
risk of bias. We resolved disagreements by discussion.
Data synthesis and statistical analysis
We reported continuous variables as means ± standard deviations, and
categorical variables as percentages. We evaluated statistical significance
in all analyses at the 0.05 level. In individual studies, we assessed the C-sta-
tistic of a model, where a 95% CI containing 0.5 indicated insufficient dis-
crimination. Calibration of a model was deemed sufficient when authors
reported a P-value of a goodness-of-fit test >0.05 and/or an O:E ratio
What’s new?
• This is the first systematic review and meta-analysis designed to
capture and evaluate a broad range of prognostic models used
for incident atrial fibrillation (AF) risk prediction, and the first to
focus specifically on models that are applicable in and have been
derived, validated and/or augmented in community cohorts.
• This work was open to any model used for incident AF predic-
tion in the community, which also enabled inclusion of models
that had not been developed for incident AF but that may have
merits for this aim. We hereby identified 21 models used for in-
cident AF prediction in community cohorts.
• This work suggests that the CHARGE-AF model is likely most
robust for incident AF prediction in terms of performance as
well as applicability in the community.
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ranging between 0.95 and 1.05. In assessing augmentation, we defined sig-
nificant improvement as a positive NRI index with a reported 95% CI that
did not contain 0. When a study reported on multiple cohorts, and pre-
sented separate data for each cohort, we assessed model performance
separately for each cohort within that study.
We performed meta-analysis to assess overall discrimination of in-
cluded models. The primary expression of associations in meta-analysis
was the summary C-statistic and corresponding 95% CI using a random
effects inverse variance model with restricted maximum likelihood esti-
mation and Hartung–Knapp corrections.14 We conducted the meta-
analyses in R using the meta and metafor packages (R Foundation for
Statistical Computing, version 3.5.1). We performed meta-analysis only
when C-statistic data for a prediction model were available for >_3
cohorts.16 When studies presented a C-statistic without 95% CI, we cal-
culated the 95% CI using methods described previously.14 In each meta-
analysis, we calculated the mean as the summary effect measure, its 95%
CI, and the I2 statistic as an expression of the heterogeneity between
studies.17 When heterogeneity in meta-analysis of C-statistics was high (I2
> 30%18), we derived a 95% prediction interval (95% PI) using methods
described previously.19 We assessed overall discrimination of models by
the summary C-statistic. When the 95% CI (or, in case of high heteroge-
neity, the 95% PI) of the summary C-statistic included 0.5, we concluded
that there was insufficient evidence that the prediction model has signifi-
cant discriminatory ability for incident AF in such populations as included
in the meta-analysis.
We assessed eligibility for inclusion into meta-analysis at the cohort
level. Cohorts with low or unclear overall risk of bias were eligible for in-
clusion into meta-analysis. When studies reported C-statistic data based
on the aggregation of multiple cohorts, and one of these cohorts was
assessed as having high overall risk of bias, we did not include the aggre-
gate C-statistic data into meta-analysis. When multiple studies reported
C-statistic data on the same cohort, we included the first published study
into the primary analysis. In the primary meta-analysis of each model, we
included cohorts with any follow-up duration.
In our primary analysis, we assessed overall discrimination of all models
that had >_3 eligible cohorts with C-statistic data. In the secondary analysis
we performed meta-analysis for each risk model that had >_3 eligible
cohorts reporting C-statistic data while applying a uniform prediction
window, and grouped cohorts according to the applied risk prediction
window (e.g. 5 or 10 years) since this is an important methodological con-
siderations when wanting to translate summary risk model performance
to clinical settings.15
We performed a sensitivity analysis in which we restricted the primary
and secondary analyses to only those cohorts that had demonstrated suf-
ficient calibration in order to assess overall discrimination among popula-
tions where the prediction model had also shown the ability to correctly
classify absolute incident AF risk. Finally, we performed a sensitivity analy-
sis in which we replaced primary and secondary meta-analyses data from
‘double’ cohorts (cohorts from the primary meta-analysis that had also
been reported on in later studies) with data on that same cohort from
Records identified in PubMed,
Embase, and CINAHL database
(n = 4714)






Records excluded, with reasons
(n = 75)
- Non-original studies (33)
- Risk model NA in primary care (10)
- No risk model/prediction rule (11)
- Risk model not derived from
  multivariable analysis (2)
- Wrong outcomes measure (4)
- AF or Afl not excluded at baseline (1)
- Selected patients/not from general
   population (12)






Figure 1 Literature flow diagram. AF, atrial fibrillation; AFl, atrial flutter; CINAHL, Cumulative Index to Nursing and Allied Health Literature; NA,
not applicable.
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any later study to assess whether later, possibly ‘more complete’ datasets
could be of influence to our conclusions from the primary and secondary
analyses.
Results
We found a total of 3873 unique references, 102 of which we sub-
jected to full-text screening. From these, we included 27 studies20–46
for our final analysis (see Figure 1).
Characteristics of included studies
The 27 included studies were based on 20 different cohorts set in
Europe (n = 8), East Asia (n = 5), North America (n = 5), and the
Middle East (n = 2) (see Supplementary material online, Table S2 for
characteristics of the included studies and cohorts). Cohort size
ranged from 646 to 1 062 073 patients, with a total of 2 978 659
unique participants. Mean age varied from 42 to 76 years, percentage
of female participants ranged from 0% to 100%. Mean follow-up of
the included cohorts varied from 3 to 20 years, with AF incidence
during follow-up ranging from 0.2% to 24.5%. Ten cohorts used AF/
Afl as the outcome, and the other 10 cohorts described only AF.
Thirteen of the 20 cohorts followed a prospective design, of which 6
cohorts applied prescheduled follow-up examinations to systemati-
cally identify AF.
Characteristics of included risk models
The included studies represented data on 21 multivariable prediction
models. Ten models had specifically been derived for predicting inci-
dent AF (Table 1). Of these, nine had been derived in community
cohorts20–28 and one had been derived in a cohort of outpatients.47
Five of the models derived for incident AF had also been externally
validated.20–24 The intended risk prediction window of models de-
rived for incident AF varied between 5 and 11 years. The FHS-AF
(Framingham Heart Study risk score for AF) model had originally
been derived for predicting 10-year incident AF risk, but had later
been recalibrated and subsequently externally validated for 5-year
risk of incident AF.33,40
We identified seven risk models that had originally been derived
for predicting other outcomes than incident AF but had been vali-
dated for this outcome in community cohorts34,48–53 and a further
four models that were incidentally employed to predict incident AF
but that had not specifically been derived as a prediction model for
that outcome23,37,44,46 (Supplementary material online, Table S3).
The number of variables incorporated into each of the included
models varied between 5 and 18, with a total of 27 distinguishable
variables/variable categories among all included risk models. Age was
the only variable used in all models. Other common variables were
hypertension history or treatment, heart failure history, sex, and
blood pressure, incorporated into 16, 16, 14, and 14 of the 21 in-
cluded models, respectively.
Risk model performance among included
cohorts
Supplementary material online, Table S4 shows the results on AF inci-
dence, discrimination, and calibration of the included simple models
among the cohorts in our search. All studies used the C-statistic to
assess model discrimination for incident AF within their cohorts.
Nine studies assessed calibration by providing both a P-value for
a goodness-of-fit test and a calibration plot in at least one of the
risk models that these studies reported on refs,20,21,24,27,29,30,32,36,40
seven studies assessed calibration only by a P-value for goodness-of-
fit test,22,26,35,39,41,43,44 two studies assessed calibration only by a cali-
bration plot,25,33 and nine studies reported neither of these calibra-
tion parameters.23,28,31,34,37,38,42,45,46
Reported C-statistics for incident AF ranged from 0.58 (95% CI
0.55–0.61)21 to 0.842 (95% CI 0.826–0.858).44 The highest C-statistic
while also showing sufficient calibration was reported in the FHS
(Framingham Heart Study) cohort on the in the incidentally used
FHS-Lubitz model with a C-statistic of 0.78 (95% CI 0.76–0.80) and
P-value of the goodness-of-fit test of 0.11.44
Augmentation of included risk models
We identified augmentation data applicable to primary care settings
for five of the included AF risk models (see Supplementary material
online, Table S5). Significant improvement was demonstrated in
CHARGE-AF (Cohorts for Heart and Aging Research in Genomic
Epidemiology) with addition of the P-wave axis35 and brain natriuretic
peptide (BNP) and/or C-reactive protein (CRP),41 in the FHS-AF
10-year model with addition of BNP and CRP,39 and in the Seirei
model with addition of ECG parameters to the model.27
Risk of bias assessment
Supplementary material online, Table S6 shows the results of the risk
of bias assessment for each cohort in the included studies. We
assessed the risk of bias of all domains as either low or unclear for all
domains except for the participants domain. For this domain, we
assessed eight cohorts employed by 10 studies as having a high risk of
bias for excluding patients for reasons with a known association with
risk of future AF.20,26,27,29,33,40,41,43,45,46
Meta-analyses
Five models were eligible for the primary meta-analysis, as shown in
Figure 2. Of these, only CHARGE-AF and the FHS-AF for 10-year risk
model had originally been derived for incident AF. All primary meta-
analyses resulted in high heterogeneity for which we calculated a 95%
PI. There were three models that resulted in a summary C-statistic
with significant 95% PI in our primary meta-analysis: CHARGE-AF
(summary C-statistic 0.71; 95% CI 0.66–0.76; I2 87%; 95% PI 0.554–
0.865; n = 8 studies; n = 58 137 patients), the FHS-AF 10-year model
(summary C-statistic 0.70; 95% CI 0.64–0.76; I2 94%; 95% PI 0.535–
0.869; n = 5 studies; n = 33 846 patients), and CHA2DS2-VASc (sum-
mary C-statistic 0.69; 95% CI 0.64–0.74; I2 100%; 95% PI 0.540–0.838;
n = 5 studies; n = 2 005 813 patients) (see Figure 3 for a comparison
of these three models).
For our secondary analysis, we were able to meta-analyse
CHARGE-AF and the FHS-AF 10-year model, each for a 5- and 10-
year prediction window (Figure 4). Only the meta-analysis of
CHARGE-AF with a 5-year prediction window resulted in significant
overall discrimination (summary C-statistic 0.72; 95% CI 0.66–0.78; I2
85%; 95% PI 0.567–0.881; n = 6 studies; n = 50 328 patients).
In our sensitivity analysis of restricting primary and secondary anal-
yses models to cohorts with sufficient calibration, we found no model
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































9722 20.6% 0.71 [0.69, 0.73]
451199 21.6% 0.64 [0.63, 0.64]
471446 19.5% 0.69 [0.66, 0.72]
11373 16.8% 0.66 [0.61, 0.71]
1062073 21.6% 0.74 [0.74, 0.75]
































































95% Prediction interval 0.554, 0.865
95% Prediction interval 0.535, 0.869
Heterogeneity: Tau2 = 0.00; I2 = 87%
Heterogeneity: Tau2 = 0.00; I2 = 94%
Heterogeneity: Tau2 = 0.00; I2 = 100%


























Models originally developed for incident AF
Models originally developed for other outcomes than incident AF
C-statistic
IV, Random, 95% CI
C-statistic
IV, Random, 95% CIWeightn
Figure 2 Primary analysis: meta-analysis of C-statistics. 95% CI, 95% confidence interval; AF, atrial fibrillation; AGES, Age, Gene and Environment-
Reykjavik Study; ARIC, Atherosclerosis Risk In Communities; CHADS2, Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, prior
Stroke or transient ischaemic attack (2 points); CHA2DS2-VASc, Congestive HF, Hypertension, Age >75 (2 points), Stroke/transient ischaemic at-
tack/thromboembolism (2 points), Vascular disease, Age 65–74, Sex category; CHARGE-AF, Cohorts for Heart and Aging Research in Genomic
Epidemiology; CI, confidence interval; EPIC, European Prospective Investigation into Cancer and Nutrition; FHS, Framingham Heart Study; FHS-AF,
Framingham Heart Study score for Atrial Fibrillation; HATCH, Hypertension, Age, stroke or Transient ischaemic attack, Chronic obstructive pulmo-
nary disease, Heart failure; IV, inverse variance; MPP-RES, Malmö Preventive Project Re-examination Study; NHIS, National Health Insurance Service;
NHIRD, National Health Insurance Research Database; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; RS, Rotterdam Study;
YMID, Yunnan Medical Insurance Database. aDerivation cohort.
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with significant overall discrimination due to high heterogeneity
(Supplementary material online, Figures S1 and S2). Our sensitivity
analysis on double cohorts in the primary and secondary analyses did
not lead to different conclusions on overall discriminatory ability of
meta-analysed models in all but one comparison (see Supplementary
material online, Table S7).
Discussion
In this systematic review and meta-analysis, we provided an overview
of prediction models for incident AF risk that are applicable in and
had been derived, validated, and/or augmented in community
cohorts. We identified 21 risk models that met these criteria, of
which 10 had specifically been derived for predicting AF incidence in
the community. In meta-analysis of C-statistics, three models showed
significant overall discrimination for AF incidence at any follow-up du-
ration and with any calibration despite high heterogeneity. Two of
those models were derived specifically for incident AF risk prediction:
CHARGE-AF and the FHS-AF 10-year model. Only CHARGE-AF
showed significant overall discrimination among cohorts with a uni-
form prediction window (the model’s originally intended 5-year
window).
Clinical relevance
The outcomes of this systematic review and meta-analysis are highly
relevant for the field of primary AF screening. Previous AF screening
programmes showed only moderate efficiency in selecting at-risk
patients from the community, with an estimated number needed to
screen of 111 among 23 studies that had screened community
cohorts for incident AF by various methods.12 Patients were often se-
lected for screening based only on age.7–9,54 The age criterion in
selecting patients for AF screening has its clinical merits since oral
anticoagulation in AF patients is indicated in all women >_65 and all
men >_75 years of age and should be considered in men aged
>_65 years in the absence of other risk factors.5,55 Age as a criterion,
however, should not be considered absolute in selecting patients for




































































































































































Figure 3 Comparison of the three models that resulted in significant 95% prediction intervals in the primary meta-analysis. 95% CI, 95% confidence
interval; 95% PI, 95% prediction interval; AF, atrial fibrillation; AGES, Age, Gene and Environment-Reykjavik Study; ARIC, Atherosclerosis Risk In
Communities; BMI, body mass index; CHA2DS2-VASc, Congestive HF, Hypertension, Age >75 (2 points), Stroke/transient ischaemic attack/throm-
boembolism (2 points), Vascular disease, Age 65–74, Sex category; CHARGE-AF, Cohorts for Heart and Aging Research in Genomic Epidemiology;
C-stat., C-statistic; ECG, electrocardiogram; EPIC, European Prospective Investigation into Cancer and Nutrition; FHS, Framingham Heart Study;
FHS-AF, Framingham Heart Study score for Atrial Fibrillation; MPP-RES, Malmö Preventive Project Re-examination Study; NA, not applicable; NHIS,
National Health Insurance Service; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; RS, Rotterdam Study; YMID, Yunnan
Medical Insurance Database. The meta-analyses of C-statistics for the outcome incident AF are grouped by cohort from which C-statistics were
reported, allowing for a comparison of multiple models’ performance within one cohort insofar as data are available.
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Heart Rhythm Week were younger than 65 years of age.56
Moreover, there is evidence that CHARGE-AF has higher discrimina-
tion among younger patients, although calibration here was lower
due to lower absolute AF risk in this younger subgroup.36 Finally, the
two studies within our search that compared multivariable models
with age alone as the predictor both found that the multivariable
models had significantly higher C-statistics for incident AF.26,34 We
conclude, therefore, that the use of multivariable risk models in
selecting patients for community AF screening is likely to result in
more efficient screening than selecting based on age alone. Given
that there is adequate stroke prevention therapy available once AF is
detected, it is likely that the use of such models in AF screening will
result in more efficient stroke prevention.5 More work on the imple-
mentation of multivariable risk models in AF screening as well as on
long-term follow-up of screening-detected AF cases, however, is nec-
essary to test these hypotheses.
Whether an immediate start of anticoagulation therapy is war-
ranted when AF is detected in younger patients with risk factors
other than high age will subsequently depend on the number and
nature of these other risk factors. However, as shown in Table 1,
most AF risk prediction models include a multitude of the variables
in the CHA2DS2-VASc score used to assess anticoagulant treat-
ment indication.5,55 In a younger patient selected for AF screening
based on a multivariable prediction model due to presence of
other risk factors than high age, an AF diagnosis is therefore likely
to still be relevant in terms of the need for anticoagulant therapy, if
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One of the aims of this work was to determine which model may
be best suitable for increasing efficiency of future primary AF screen-
ing efforts. Our work showed that there are ample AF risk models to
choose from, however with one model that currently stands out be-
tween the others: CHARGE-AF. Despite heterogeneity in included
cohorts, CHARGE-AF showed significant summary discrimination
over a relatively short (5-year) risk prediction window. The model
contains variables that are generally easy to extract from health
records, and requires only body measurements that are easily obtain-
able (height, weight, and blood pressure). The FHS-AF model, in con-
trast, though performing nearly as well in overall discrimination,
requires variables ‘significant murmur’ and ECG variables which are
less easy to acquire or interpret for many care professionals.
Concluding, CHARGE-AF currently seems the most suitable predic-
tion model for incident AF, and likely has merits as a low-cost triage
test for future primary AF screening efforts.
Derivation, validation, and augmentation
In risk models derived for incident AF in community cohorts, there
was a trend that the derivation cohort had the highest C-statistic
compared with external validation cohorts. The only exception was
CHARGE-AF, where Pfister et al.36 reported a C-statistic of 0.808.
Calibration of CHARGE-AF in their cohort, however, was insufficient
(P-value for goodness-of-fit test <0.001 and O: E ratio 0.47) due to a
systematic overestimation of 5-year AF risk in all risk deciles. One ex-
planation lies in the differences in demographics, as Pfister’s cohort
was younger and had lower baseline prevalence of diabetes mellitus
than the CHARGE-AF derivation cohorts. Depending on whether
one’s aim is to distinguish high from low-risk patients, or to predict
absolute 5-year incident AF risk, a researcher may use this knowledge
to decide whether or not to recalibrate a model for his own target
population. In augmentation studies, we saw that addition of BNP
and CRP to a model seemed most promising in terms of improving
risk classification. We note, however, that the significance of an added
value of BNP and CRP to CHARGE-AF was not consistent, and that
the augmentation studies provided no information on the added
costs of augmentation parameters relative to those of acquiring the
simple model risk score.29
Previous work
Previous systematic reviews have focused on individual predictors
for AF,58,59 on AF as a risk factor for other outcomes,60,61 or on risk
models for adverse outcomes in AF patients.62,63 However, to our
knowledge, this is the first systematic review and meta-analysis on
performance of incident AF risk prediction models, and the first with
a focus on such risk models validated in and applicable to the
community.
Future work
Future studies could focus on finding optimal cut-offs for the more
promising AF prediction models, and to find the most cost-
effective use of multivariable models within various screening
schemes. Researchers may opt here, e.g. for either a dichotomiza-
tion into patients with higher and lower risk or assigning patients
to one of multiple risk strata. Patients at higher risk could be of-
fered a more intensive, sensitive screening scheme (e.g. multiple-
point screening or Holter monitoring) when compared with
patients at low risk (single point or no screening). Further research
could also assess whether implementation of multivariable models
in AF screening could be aided by software that automatically
extracts patient data from health records, informs the physician of
a patient’s current risk category, and suggests parameters that
should be updated for a more accurate current AF risk
stratification.
Strengths and limitations
This study has a number of strengths. First, we included only
studies performed in community cohorts, which contributed to
the value of our results for primary care AF screening. Second,
we included any risk model that was used to predict risk of inci-
dent AF. This enabled us to expand our scope to models that
had originally not been intended for predicting incident AF, but
that may have merits in predicting this outcome. Third, we at-
tributed high bias to studies that excluded or over-represented
patients based on factors that are likely to be associated with
risk of incident AF, further contributing to the generalizability of
our results to the community. Fourth, we included only the C-
statistic of raw, non-bootstrapped data into meta-analysis in or-
der to not bias the meta-analysis with potentially overly narrow
confidence intervals. Finally, we refrained from meta-regression
or subgroup meta-analysis based on e.g. a subdivision of cohorts’
mean age, AF incidence or region, to explain the heterogeneity
in our results. Such analyses from aggregate data are known to
have a high risk of especially ecological bias and are inferior to
subgroup results derived from individual participant data
(IPD).14 An IPD meta-analysis, however, was not the scope of
the current study.
The primary limitation of our study is the high heterogeneity of
included studies. We attempted to cope with this limitation by
performing sensitivity analyses and by calculating a 95% PI in our
meta-analyses with high heterogeneity. The outcomes of our meta-
analyses with significant 95% PI can be considered generalizable to
such populations as included into those meta-analyses, despite high
heterogeneity. As a second limitation, we did not provide a meta-
analysis on model calibration since such analyses are often challeng-
ing due to a lack of calibration measures reported among studies.14
Indeed, we found that meta-analysable data on calibration was
poorly reported on among included studies (Supplementary mate-
rial online, Table S4). Moreover, summarizing O:E data would have
automatically excluded those models that were not originally
intended for incident AF, since expected incident AF rates would
never have been defined for such models. We addressed calibration
by performing a sensitivity analysis among cohorts which had dem-
onstrated sufficient calibration by their applied risk model(s). A third
limitation is that we included both prospective and retrospective co-
hort studies. This may have introduced bias as AF is not always
symptomatic64 and asymptomatic patients are less likely to undergo
rhythm evaluation when left to their physicians’ discretion than
when ECG is performed in the context of a prescheduled follow-up.
The restriction of our search to studies written in English which we
applied for quality-related as well as practical reasons, finally, has
been found not to lead to significant bias.65
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Conclusion
We provided an overview of prediction models for incident AF risk
that are applicable in and have been derived, validated, and/or aug-
mented in community cohorts. We identified 21 risk models that
met these criteria. Of these, CHARGE-AF seemed the most robust
in terms of performance as well as applicability in the community.
Supplementary material
Supplementary material is available at Europace online.
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